Clinical trial
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Ascend
NCT07592689 is registered in ClinicalTrials.gov with Definium Therapeutics US, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Ascend
- Lead sponsor
- Definium Therapeutics US, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- May 10, 2026
- Completion date
- June 30, 2028
- Enrollment
- 165 (estimated)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.